Clinical trial · Interventional
HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC
HAIC Combined With Lenvatinib and Tislelizumab Versus D-TACE Combined With Lenvatinib and Tislelizumab in Advanced Unresectable Hepatocellular Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Drug-eluting Bead-Transarterial chemoembolization (D-TACE) is the most widely used palliative treatment for hepatocellular carcinoma (HCC) patients. While a number of studies demonstrate poor effect of D-TACE for patients in Advanced Unresectable HCC. The investigators previous study also revealed similar results in Advanced Unresectable HCC patients treated with D-TACE. Recently, the investigators previous study demonstrated that, compared with D-TACE, hepatic arterial infusion chemotherapy (HAIC) may improve tumor response in Advanced Unresectable HCC. Thus, the investigators carried out this prospective nonrandomized control to demonstrate the superiority of HAIC-based combination therapy over D-TACE-based combination therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Unresectable Hepatocellular Carcinoma | Hepatocellular Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| D-TACE | Drug | — | UNRESOLVED |
| HAIC | Drug | — | UNRESOLVED |
| Lenvatinib | Drug | Lenvatinib | ALIAS |
| tislelizumab | Drug | Tislelizumab | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- HAIC+lenvatinib+tislelizumab
- description
- Hepatic Arterial Infusion Chemotherapy Combined With lenvatinib and tislelizumab
- interventionNames
- Drug: HAIC
- Drug: Lenvatinib
- Drug: tislelizumab
- type
- EXPERIMENTAL
- label
- D-TACE+lenvatinib+tislelizumab
- description
- Transarterial chemoembolization with drug-eluting beads Combined With lenvatinib and tislelizumab
- interventionNames
- Drug: D-TACE
- Drug: HAIC
- Drug: Lenvatinib
Primary outcomes (4)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with advanced unresectable hepatocellular carcinoma treated by D- TACE, or HAIC combined with Lenvatinib and Tislelizumab as initial treatment * Age between 18 and 75 years * Child-Pugh A or B liver function * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * Adequate hematologic blood counts (white blood cell count \>3ⅹ109/L, absolute neutrophil count \>1.5ⅹ109/L, platelet count \>10ⅹ109/L, hemoglobin concentration \>85 g/L * No extrahepatic metastasis Exclusion Criteria: * Severe underlying cardiac, pulmonary, or renal diseases * History of a second primary malignant tumor * Incomplete medical data * Loss to follow-up.
References
Publications (0)
Data not yet available